Search results for Tiragolumab

Tiragolumab Biosimilar – Anti-TIGIT, VSIG9, VSTM3 mAb – Research Grade, ProteoGenix, PX-TA1487

Description of Tiragolumab Biosimilar - Anti-TIGIT, VSIG9, VSTM3 mAb - Research Grade Introduction Tiragolumab is a biosimilar antibody that targets the T cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) protein. It is also known as anti-TIGIT, VSIG9, VSTM3 monoclonal antibody (mAb) and is used in research grade applications. This article will provide a scientific description of Tiragolumab, including its structure, activity, and potential applications. Structure of Tiragolumab Tiragolumab is a type of monoclonal antibody, which means it is a laboratory-produced protein that is designed to target a specific molecule in the body. It is a fully humanized IgG1 antibody, meaning it is derived from human cells and has a specific type of constant region called IgG1. This structure allows Tiragolumab to bind to its target, TIGIT, with high specificity and affinity. Activity of Tiragolumab TIGIT is a protein that is expressed on the surface of immune cells, including T cells and natural killer (NK) cells. It is known to act as an immune checkpoint, meaning it regulates the activity of these cells. TIGIT binds to a protein called poliovirus receptor (PVR) on other cells, which can inhibit the function of T cells and NK cells. This can lead to a suppression of the immune response, which is beneficial in certain situations, such as during pregnancy or in the prevention of autoimmune diseases. However, in cancer, TIGIT can be overexpressed on tumor-infiltrating immune cells, leading to immune evasion and tumor progression. Tiragolumab works by binding to TIGIT, blocking its interaction with PVR and preventing the inhibitory signal. This allows for the activation and function of T cells and NK cells, which can then mount an effective immune response against cancer cells. In addition, Tiragolumab can also promote the activation of dendritic cells, which are important for initiating an immune response. Applications of Tiragolumab Tiragolumab is currently being investigated in clinical trials as a potential therapeutic agent for various types of cancer, including non-small cell lung cancer (NSCLC), head and neck cancer, and ovarian cancer. It is being evaluated both as a monotherapy and in combination with other cancer treatments, such as chemotherapy and other immunotherapies. In addition to its potential as a cancer treatment, Tiragolumab also has potential applications in other diseases where TIGIT plays a role, such as autoimmune diseases and infectious diseases. It may also have a role in combination with other immune checkpoint inhibitors, such as anti-PD-1 and anti-CTLA-4 antibodies, to enhance their effectiveness. Conclusion Tiragolumab is a biosimilar antibody that targets TIGIT, a protein involved in immune regulation. Its structure as a fully humanized IgG1 antibody allows for high specificity and affinity for its target. By blocking the inhibitory signal of TIGIT, Tiragolumab can promote the activation and function of immune cells, making it a potential therapeutic agent for cancer and other diseases. Further research and clinical trials are needed to fully understand the potential of Tiragolumab in various applications.

Tiragolumab, Kyinno, KB-1065

Tiragolumab, Abbexa, abx831446

Tiragolumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting TIGIT/VSIG9/VSTM3, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Tiragolumab is a humanized monoclonal antibody. Tiragolumab targets TIGIT and directly or indirectly activates the anti-tumor immune response by acting on the activation pathways of APC and T cells and NK cells to achieve the purpose of eliminating tumor cells.

Tiragolumab ELISA Kit, ProteoGenix, KPTX264

Description of Tiragolumab ELISA Kit The Structure of Tiragolumab ELISA Kit Tiragolumab ELISA Kit is a highly specific and sensitive tool for the detection and quantification of Tiragolumab, a monoclonal antibody targeting a novel immune checkpoint protein. The kit is designed for use in research and clinical laboratories, providing a reliable and accurate method for measuring the levels of Tiragolumab in various biological samples. The kit contains all the necessary components for performing an enzyme-linked immunosorbent assay (ELISA) including pre-coated microplates, standards, controls, and detection reagents. The microplates are coated with a capture antibody that specifically binds to Tiragolumab, while the detection reagents consist of a biotinylated detection antibody and an enzyme-conjugated streptavidin. The streptavidin-enzyme complex reacts with a substrate to produce a colorimetric signal, which is directly proportional to the amount of Tiragolumab present in the sample. The structure of Tiragolumab ELISA Kit allows for a simple and user-friendly workflow, with minimal hands-on time and a short incubation period. The kit is also available in a variety of formats including 96-well and 384-well plates, allowing for flexibility in sample size and throughput. The Activity of Tiragolumab ELISA Kit Tiragolumab ELISA Kit has been extensively validated for its specificity, sensitivity, and precision. The kit has a low limit of detection, with the ability to detect Tiragolumab at concentrations as low as 0.1 ng/mL. It also has a wide dynamic range, allowing for the accurate quantification of Tiragolumab in a variety of sample types. The activity of Tiragolumab ELISA Kit is based on the principle of competitive ELISA, where the amount of Tiragolumab present in the sample competes with a fixed amount of biotinylated Tiragolumab for binding to the capture antibody. The colorimetric signal produced is inversely proportional to the amount of Tiragolumab in the sample, allowing for precise quantification. The kit also demonstrates excellent intra- and inter-assay variability, ensuring reproducibility and reliability of results. It has been tested and validated for use with various sample types including serum, plasma, and cell culture supernatants, making it a versatile tool for researchers and clinicians. The Application of Tiragolumab ELISA Kit Tiragolumab is a promising therapeutic target in the field of cancer immunotherapy. It is a monoclonal antibody that binds to TIGIT, a protein expressed on immune cells that inhibits their function. By blocking TIGIT, Tiragolumab enhances the anti-tumor immune response, making it a potential treatment option for various types of cancer. Tiragolumab ELISA Kit is a valuable tool for studying the pharmacokinetics and pharmacodynamics of Tiragolumab in preclinical and clinical settings. It can be used to measure the levels of Tiragolumab in patient samples, providing insights into drug efficacy and potential biomarkers for response to treatment. The kit can also be used in drug development and quality control, ensuring the accurate and consistent measurement of Tiragolumab levels in different formulations and batches. Additionally, Tiragolumab ELISA Kit can be used in basic research to investigate the role of TIGIT in cancer and other diseases, as well as in the development of new therapeutics targeting this immune checkpoint. In Conclusion Tiragolumab ELISA Kit is a powerful tool for the detection and quantification of Tiragolumab, a promising therapeutic antibody targeting TIGIT. Its unique structure, high activity,

Tiragolumab ELISA Kit, Abbexa, abx395153

Tiragolumab ELISA Kit is a quantitative ELISA kit for detection of Tiragolumab.Tiragolumab is an investigational, fully human monoclonal IgG1 antibody designed to prevent PVR-TIGIT interaction.

Tiragolumab Biosimilar - Research Grade, ichor.bio, ICH5078

Detects human TIGIT. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Tiragolumab.

Research Grade Tiragolumab (HS739016), abinScience, HS739016

TIGIT (Tiragolumab Biosimilar) Human Monoclonal Antibody#28275, Cell Signaling Technology (CST), 28275

TIGIT (Tiragolumab Biosimilar) Human Monoclonal Antibody was confirmed to bind to its intended target protein TIGIT using flow cytometry.